145 related articles for article (PubMed ID: 27540836)
1. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
McQuade JL; Posada LP; Lecagoonporn S; Cain S; Bassett RL; Patel SP; Hwu WJ; Hwu P; Davies MA; Bedikian AY; Amaria RN
Melanoma Res; 2016 Dec; 26(6):604-608. PubMed ID: 27540836
[TBL] [Abstract][Full Text] [Related]
2. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
3. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Schadendorf D; Hauschild A; Ugurel S; Thoelke A; Egberts F; Kreissig M; Linse R; Trefzer U; Vogt T; Tilgen W; Mohr P; Garbe C
Ann Oncol; 2006 Oct; 17(10):1592-7. PubMed ID: 17005632
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
[TBL] [Abstract][Full Text] [Related]
5. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
6. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Masucci GV; Månsson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Melanoma Res; 2006 Aug; 16(4):357-63. PubMed ID: 16845332
[TBL] [Abstract][Full Text] [Related]
7. The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Yoon C; Papadopoulos NE; Camacho LH; McIntyre S; Alvarado GC; Bedikian AY; Hwu P; Kim KB
Melanoma Res; 2010 Feb; 20(1):43-7. PubMed ID: 19952963
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Lewis KD; Gibbs P; O'Day S; Richards J; Weber J; Anderson C; Zeng C; Baron A; Russ P; Gonzalez R
Cancer Invest; 2005; 23(4):303-8. PubMed ID: 16100942
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Kim KB; Hwu WJ; Papadopoulos NE; Bedikian AY; Camacho LH; Ng C; Hernandez IM; Frost AM; Jack MA; Hwu P
Cancer Chemother Pharmacol; 2009 Jun; 64(1):161-7. PubMed ID: 19002462
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Bael TE; Peterson BL; Gollob JA
Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Alrwas A; Papadopoulos NE; Cain S; Patel SP; Kim KB; Deburr TL; Bassett R; Hwu WJ; Bedikian AY; Davies MA; Woodman SE; Hwu P
Melanoma Res; 2014 Aug; 24(4):342-8. PubMed ID: 24743052
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
[TBL] [Abstract][Full Text] [Related]
14. Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Chiarion-Sileni V; Guida M; Ridolfi L; Romanini A; Del Bianco P; Pigozzo J; Brugnara S; Colucci G; Ridolfi R; De Salvo GL;
Br J Cancer; 2011 Jun; 104(12):1816-21. PubMed ID: 21610711
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Laber DA; Okeke RI; Arce-Lara C; Taft BS; Schonard CL; McMasters KM; Kloecker GH; Miller DM
J Cancer Res Clin Oncol; 2006 Sep; 132(9):611-6. PubMed ID: 16741726
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.
Tas F; Argon A; Camlica H; Topuz E
Melanoma Res; 2005 Dec; 15(6):543-8. PubMed ID: 16314741
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
[TBL] [Abstract][Full Text] [Related]
19. A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.
Strauss SJ; Marples M; Napier MP; Meyer T; Boxall J; Rustin GJ
Br J Cancer; 2003 Nov; 89(10):1901-5. PubMed ID: 14612900
[TBL] [Abstract][Full Text] [Related]
20. A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.
Mitchell D; Bergendahl G; Ferguson W; Roberts W; Higgins T; Ashikaga T; DeSarno M; Kaplan J; Kraveka J; Eslin D; Werff AV; Hanna GK; Sholler GL
Pediatr Blood Cancer; 2016 Jan; 63(1):39-46. PubMed ID: 26235333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
